Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Drug utilization, safety and clinical use of Actos and Avandia.

Marks DH.

Int J Risk Saf Med. 2013 Jan 1;25(1):39-51. doi: 10.3233/JRS-120581. Review.

PMID:
23442297
2.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

3.

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.

Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J.

Health Technol Assess. 2004 Apr;8(13):iii, ix-x, 1-91. Review.

4.

A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A.

Pharmacoeconomics. 2007;25(1):39-54. Erratum in: Pharmacoeconomics. 2007;25(3):237.

PMID:
17192117
5.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
6.

Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.

Neeser K, L├╝bben G, Siebert U, Schramm W.

Pharmacoeconomics. 2004;22(5):321-41. Review.

PMID:
15061682
7.

Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus.

Balkrishnan R, Arondekar BV, Camacho FT, Shenolikar RA, Horblyuk R, Anderson RT.

Clin Ther. 2007;29 Spec No:1306-15.

PMID:
18046930
8.

Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.

Niyomnaitham S, Page A, La Caze A, Whitfield K, Smith AJ.

BMC Health Serv Res. 2014 Apr 4;14:151. doi: 10.1186/1472-6963-14-151.

9.

Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone.

Stewart KA, Natzke BM, Williams T, Granger E, Casscells SW, Croghan TW.

Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1048-52. doi: 10.1002/pds.1819.

PMID:
19655338
10.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
12.

How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?

Hsu JC, Ross-Degnan D, Wagner AK, Zhang F, Lu CY.

Clin Ther. 2015 Jul 1;37(7):1420-1432.e1. doi: 10.1016/j.clinthera.2015.04.006. Epub 2015 May 11.

PMID:
25976425
13.

Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.

Balkrishnan R, Arondekar BV, Camacho FT, Shenolikar RA, Horblyuk R, Anderson RT.

Clin Ther. 2007 Jun;29(6 Pt 1):1306-15.

PMID:
18036392
14.

Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.

Jain R, Mullins CD, Lee H, Wong W.

Res Social Adm Pharm. 2012 Jan-Feb;8(1):47-59. doi: 10.1016/j.sapharm.2010.12.003. Epub 2011 Jul 6.

PMID:
21733760
15.

Glitazones and the cardiovascular system.

Devchand PR.

Curr Opin Endocrinol Diabetes Obes. 2008 Apr;15(2):188-92. doi: 10.1097/MED.0b013e3282f79b20. Review.

PMID:
18316956
16.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
17.

Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.

Tunis SL, Minshall ME, St Charles M, Pandya BJ, Baran RW.

Curr Med Res Opin. 2008 Nov;24(11):3085-96. doi: 10.1185/03007990802434874 . Epub 2008 Oct 2.

PMID:
18826750
18.

Pioglitazone and rosiglitazone for diabetes.

[No authors listed]

Drug Ther Bull. 2001 Sep;39(9):65-8. Review.

PMID:
11586802
19.

A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006.

Casscells SW, Granger E, Swedorske J, Goldhammer R, Shaheen M, Dorris J, Hong A, Wiktor M.

Am J Ther. 2008 May-Jun;15(3):198-205. doi: 10.1097/MJT.0b013e31817534d5.

PMID:
18496256
20.

Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.

Hall GC, Smith HT, Curtis B, McMahon AD.

Int J Clin Pract. 2011 May;65(5):586-91. doi: 10.1111/j.1742-1241.2011.02648.x.

PMID:
21489082
Items per page

Supplemental Content

Write to the Help Desk